A Case Report of a Patient on Long-Term Follow-Up

Total Page:16

File Type:pdf, Size:1020Kb

A Case Report of a Patient on Long-Term Follow-Up □ CASE REPORT □ Primary Hepatic Carcinoid Tumor with Carcinoid Syndrome and Carcinoid Heart Disease: A Case Report of a Patient on Long-Term Follow-up Tatsuhiko TOHYAMA, Kazuhiro MATSUI* and Kiyohide KITAGAWA** Abstract PHCT (5). When PHCT is confined to a single lobe, surgical resection should be taken into consideration. Otherwise, We report a 57-year-old woman with a primary he- transarterial embolization (TAE) might be effective for some patic carcinoid tumor who had been suffering from cases (1, 5). For unresectable PHCT, octreotide acetate symptoms due to carcinoid syndrome and carcinoid heart (OA), a somatostatin analogue, has been used to prevent disease for more than 9 years. Long-term injection of various symptoms derived from carcinoid (6–8). octreotide acetate was fairly effective to relieve the symp- This report refers to a case of PHCT that showed severe toms due to carcinoid syndrome, but its tumor contrac- attacks of carcinoid syndrome at the onset of the disease and tion effect was not confirmed. The massive ascites in the cardiac insufficiency due to CHD in the latter stage. follow-up period appeared to be diminished to a certain Continuous treatment with OA was fairly effective in reliev- extent by timely chemotherapy including cisplatin. The ing the symptoms, which reappeared frequently for more patient died of multi-organ failure about 9 years after the than 9 years. onset of disease. Autopsy confirmed a primary hepatic carcinoid tumor with limited distant metastases. Clinical Summary (Internal Medicine 44: 958–962, 2005) A 51-year-old woman visited our clinic in June 1994, be- Key words: primary hepatic carcinoid tumor, carcinoid heart cause of paroxysmal flushing in the face and extremities for disease, carcinoid syndrome, octreotide acetate, two years, severe watery diarrhea for one year, and bouts of carcinoid tumor, primary hepatic epigastric pain appearing for no specific reason. On the first medical examination, flushing was observed in extensive areas of the skin including her face; no cardiac murmurs were audible; hepatomegaly was palpable in the epigastric Introduction region. The essential laboratory data recorded on her first ad- mission are shown in the left columns of Table 1. The liver Carcinoid tumors seldom occur primarily in the liver, al- function tests were within normal limits, except for a slight though extrahepatic counterparts, especially those in the gas- increase of total bilirubin. The serum levels of serotonin and trointestinal tract, are common. The rarity of primary hepatic urinary 5-hydroxyindoleacetic acid (5-HIAA) were markedly carcinoid tumor (PHCT) makes it difficult for clinicians to increased. The level of human antinatriuretic peptide diagnose it precisely, which is not until autopsy ascertains (HANP) showed a slight increase. Computed tomography PHCT (1). Since carcinoid tumors frequently show an indo- (CT) revealed a hypervascular tumor, measuring 182.4 cm3 lent clinical course, clinicians have to confront various com- in volume, in the right superior segment of the liver, and plications such as carcinoid syndrome and carcinoid heart daughter nodules up to 1 cm in diameter scattered in the bi- disease (CHD) during a long-term follow-up period. CHD is lateral lobes (Fig. 1A). Histological examination of the bi- one of the common complications of carcinoid tumor (2–4), opsy specimens from the main tumor revealed a carcinoid whereas carcinoid syndrome is seldom present at the onset of tumor. The primary site was radiologically investigated From the Department of Internal Medicine, Kohryo Clinic, Takaoka, *the Department of Legal Medicine, Toyama Medical and Pharmaceutical University, Toyama and **the Department of Radiology, Takaoka Kohseiren Hospital, Takaoka Received for publication September 16, 2004; Accepted for publication May 11, 2005 Reprint requests should be addressed to Dr. Tatsuhiko Tohyama, the Department of Internal Medicine, Kohryo Clinic, 23-1 Nomura, Takaoka, Toyama 933-0014 958 Internal Medicine Vol. 44, No. 9 (September 2005) Primary Hepatic Carcinoid Tumor Table 1. Laboratory Results in Early and Late Stage: December 1994 and June 2001 December 1994 June 2001 normal range Hemoglobin 12.6 10.2 12–16 g/dl Erythrocyte sediment rate 6 90 3–8 mm/h AST/ALT 13/8 125/54 12–31/8–40 IU/l Alkaline phosphatase 120 7,460 100–330 IU/l Total bilirubin 1.25 5.2 0.22–1.20 mg/dl Creatinine 0.9 1.3 0.2–0.8 mg/dl Serotonin 143.0 139.2 10–20 mcg/dl Urinary 5-HIAA 97.9 82.1 0.5–5.0 mg/day HANP 97.0 – <43 pg/ml Plasma renin activity 0.5 – 0.1–2.0 ng/ml/h Plasma aldosterone 8.2 – 3.6–24 ng/dl AST: aspartate aminotransferase, ALT: alanine aminotransferase, Urinary 5-HIAA: urinary 5-hydoxyin- doleacetic acid, HANP: human antinatriuretic peptide. A B Figure 1. Computed tomography (CT) of the liver. (A). The CT image in December 1994 shows a hypervascular tumor with a volume of 182.4 cm3 in the right upper segment. (B). The CT image in February 2001 reveals not only the main tumor but also numerous daughter tumors in the bilateral lobe (total volume of the tumors, 450 cm3). throughout the systemic organs, including the gastro-intesti- patient suffered from so-called “carcinoid peritonitis”, char- nal tract and pulmonary system, but no lesions other than the acterized by massive ascites due to implantation of carcinoid liver tumors were discovered. cells in the peritoneum. Ascites was accompanied by hemor- The clinical course of the patient is summarized in sche- rhage and a cell count of 304/l. The cells consisted of lym- matic diagram (Fig. 2). Briefly, hormonal therapy with a phocytes (52%) and carcinoid cells (46%). On this occasion, somatostatin analogue, octreotide acetate (OA), was begun at the ascites was controlled with intraperitoneal infusion ther- an initial dose of 50 to 100 mcg day, since the patient refused apy of cisplatin. One year before death, her liver function surgery. Shortly after the commencement of therapy, the gradually worsened with flushing attacks and she had symptoms such as flushing and diarrhea appeared to be im- marked edema of the lower limbs. However, the serum level proving and the serum level of serotonin and urinary 5- of serotonin and urinary 5HIAA remained unchanged (see HIAA decreased. One year later, however, her symptoms the right columns of Table 1). The hepatic main tumor en- relating to the carcinoid syndrome were accelerated again. larged to two and half times of the initial size (liver tumor Gradual OA dose escalation to 400–600 mcg day relieved volume by CT-image analyses, 450 cm3 ), and numerous these symptoms. Six years after onset of the disease, the intrahepatic metastases were detected in the bilateral lobe Internal Medicine Vol. 44, No. 9 (September 2005) 959 TOHYAMA et al Figure 2. Schematic diagram of the clinical course. (Fig. 1B). On the other hand, a two-dimensional echocardi- ography showed remarkable dilatation of the right ventricu- lar chamber and subsequent compression of the left ventri- cular chamber with paradoxical motion of the interventri- cular septum. Thus, the patient died of multi-organ failure in July 2001, about 9 years after the onset of disease. Pathological Findings The liver measured 18×15×12 cm and weighed 1,520 g. The cut surfaces of the liver revealed a massive10 cm- diameter tumor in the right lobe and several daughter tumors of up to 3 cm in diameter in the bilateral lobes. The main tumor was light-gray to yellowish in color with extensive ne- crosis and focal hemorrhage (Fig. 3). Metastatic tumors were not discovered in the lung but observed in the vertebral bones, including the thoracic and lumbar vertebrae. Detailed macroscopic investigation did not show any tumors in the other organs including the gastro-intestinal tract. Figure 3. Macroscopic findings of the liver. The cut surface re- The right atrium and ventricle of the heart were markedly veals the main tumor in the right lobe and several daughter tu- dilated with patchy thickening of the endocardium, and the mors in the bilateral lobe. tricuspid and pulmonary arterial valves were remarkably hypertrophic with fibrous thickening, which caused valvular stenosis and regurgitation (Fig. 4). The lower lobe of the left Microscopic findings lung was atelectatic with diffuse fibrinous pneumonia. There The main tumor and satellite lesions of the liver were were no infectious foci in the other organs. composed of round and columnar cells with a uniform round 960 Internal Medicine Vol. 44, No. 9 (September 2005) Primary Hepatic Carcinoid Tumor A Figure 4. Horizontal cut surface of the heart. The right-sided chambers were markedly dilated. Note patchy or diffuse fibrous thickening of the tricuspid valve and endocardium. nucleus in a pale eosinophilic cytoplasm. Mitotic figures were very rare (0–1/10 HPF). The cells were arranged in nests and trabeculae, with fibrous septa in some location (Figs. 5A and 5B). An organoid pattern was also observed in some areas. The main tumor had extensive necrosis, which appeared to be caused partly by chemotherapy during the clinical course and chiefly by circulatory insufficiency at the terminal stage. Argyrophilic granules of varying stainability in tumor cells were demonstrated by Grimelius stain. Based B on these histological features, the liver tumors were diag- nosed as (typical) carcinoid tumors according to the criteria proposed by the WHO (9). The metastatic tumors in the ver- tebral bones and lymph nodes of the mesenterium showed the histological features similar to those of the liver tumors. The representative tissue sections of 4 m-thickness were cut from the tissue blocks for immunohistochemistry. Im- munohistochemical staining for pan-cytokeratin (AE1/AE3, Boehringer, Manheim, Germany; dilution, 1 : 200), chromo- granin A (DAKO, Kyoto, Japan; dilution, 1 : 100) (Fig.
Recommended publications
  • Carcinoid) Tumours Gastroenteropancreatic
    Downloaded from gut.bmjjournals.com on 8 September 2005 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, R Thakker, S Aylwin, D Breen, K Britton, K Buchanan, P Corrie, A Gillams, V Lewington, D McCance, K Meeran, A Watkinson and on behalf of UKNETwork for neuroendocrine tumours Gut 2005;54;1-16 doi:10.1136/gut.2004.053314 Updated information and services can be found at: http://gut.bmjjournals.com/cgi/content/full/54/suppl_4/iv1 These include: References This article cites 201 articles, 41 of which can be accessed free at: http://gut.bmjjournals.com/cgi/content/full/54/suppl_4/iv1#BIBL Rapid responses You can respond to this article at: http://gut.bmjjournals.com/cgi/eletter-submit/54/suppl_4/iv1 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Topic collections Articles on similar topics can be found in the following collections Stomach and duodenum (510 articles) Pancreas and biliary tract (332 articles) Guidelines (374 articles) Cancer: gastroenterological (1043 articles) Liver, including hepatitis (800 articles) Notes To order reprints of this article go to: http://www.bmjjournals.com/cgi/reprintform To subscribe to Gut go to: http://www.bmjjournals.com/subscriptions/ Downloaded from gut.bmjjournals.com on 8 September 2005 iv1 GUIDELINES Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours J K Ramage*, A H G Davies*, J ArdillÀ, N BaxÀ, M CaplinÀ, A GrossmanÀ, R HawkinsÀ, A M McNicolÀ, N ReedÀ, R Sutton`, R ThakkerÀ, S Aylwin`, D Breen`, K Britton`, K Buchanan`, P Corrie`, A Gillams`, V Lewington`, D McCance`, K Meeran`, A Watkinson`, on behalf of UKNETwork for neuroendocrine tumours ..............................................................................................................................
    [Show full text]
  • What You Should Know About Familial Adenomatous Polyposis (FAP)
    What you should know about Familial Adenomatous Polyposis (FAP) FAP is a very rare condition that accounts for about 1% of new cases of colorectal cancer. People with FAP typically develop hundreds to thousands of polyps (adenomas) in their colon and rectum by age 30-40. Polyps may also develop in the stomach and small intestine. Individuals with FAP can develop non-cancerous cysts on the skin (epidermoid cysts), especially on the scalp. Besides having an increased risk for colon polyps and cysts, individuals with FAP are also more likely to develop sebaceous cysts, osetomas (benign bone tumors) of the jaw, impacted teeth, extra teeth, CHRPE (multiple areas of pigmentation in the retina in the eye) and desmoid disease. Some individuals have milder form of FAP, called attenuated FAP (AFAP), and develop an average of 20 polyps at a later age. The risk for cancer associated with FAP If left untreated, the polyps in the colon and rectum will develop in to cancer, usually before age 50. Individuals with FAP also have an increased risk for stomach cancer, papillary thyroid cancer, periampullary carcinoma, hepatoblastoma (in childhood), and brain tumors. The risks to family members FAP is caused by mutations in the Adenomatous Polyposis Coli (APC) gene. Approximately 1/3 of people with FAP do not have family history of the disease, and thus have a new mutation. FAP is inherited in a dominant fashion. Children of a person with an APC mutation have a 50% risk to inherit the mutation. Brothers, sisters, and parents of individuals with FAP should also be checked to see if they have an APC mutation.
    [Show full text]
  • Cholangiocarcinoma 2020: the Next Horizon in Mechanisms and Management
    CONSENSUS STATEMENT Cholangiocarcinoma 2020: the next horizon in mechanisms and management Jesus M. Banales 1,2,3 ✉ , Jose J. G. Marin 2,4, Angela Lamarca 5,6, Pedro M. Rodrigues 1, Shahid A. Khan7, Lewis R. Roberts 8, Vincenzo Cardinale9, Guido Carpino 10, Jesper B. Andersen 11, Chiara Braconi 12, Diego F. Calvisi13, Maria J. Perugorria1,2, Luca Fabris 14,15, Luke Boulter 16, Rocio I. R. Macias 2,4, Eugenio Gaudio17, Domenico Alvaro18, Sergio A. Gradilone19, Mario Strazzabosco 14,15, Marco Marzioni20, Cédric Coulouarn21, Laura Fouassier 22, Chiara Raggi23, Pietro Invernizzi 24, Joachim C. Mertens25, Anja Moncsek25, Sumera Rizvi8, Julie Heimbach26, Bas Groot Koerkamp 27, Jordi Bruix2,28, Alejandro Forner 2,28, John Bridgewater 29, Juan W. Valle 5,6 and Gregory J. Gores 8 Abstract | Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes.
    [Show full text]
  • Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach
    International Journal of Molecular Sciences Review Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach Isabella Lurje 1,† , Zoltan Czigany 1,† , Jan Bednarsch 1, Christoph Roderburg 2,3, Peter Isfort 4, Ulf Peter Neumann 1,5 and Georg Lurje 1,* 1 Department of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] (I.L.); [email protected] (Z.C.); [email protected] (J.B.); [email protected] (U.P.N.) 2 Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] 3 Department of Gastroenterology/Hepatology, Campus Virchow Klinikum and Charité Mitte, Charité University Medicine Berlin, 13353 Berlin, Germany 4 Department for Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] 5 Department of Surgery, Maastricht University Medical Centre (MUMC), 6229 ET Maastricht, The Netherlands * Correspondence: [email protected] † Both authors contributed equally to this work. Received: 9 March 2019; Accepted: 21 March 2019; Published: 22 March 2019 Abstract: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its mortality is third among all solid tumors, behind carcinomas of the lung and the colon. Despite continuous advancements in the management of this disease, the prognosis for HCC remains inferior compared to other tumor entities. While orthotopic liver transplantation (OLT) and surgical resection are the only two curative treatment options, OLT remains the best treatment strategy as it not only removes the tumor but cures the underlying liver disease. As the applicability of OLT is nowadays limited by organ shortage, major liver resections—even in patients with underlying chronic liver disease—are adopted increasingly into clinical practice.
    [Show full text]
  • Case Report Metastasis of Pancreatic Cancer Within Primary Colon Cancer by Overtaking the Stromal Microenvironment
    Int J Clin Exp Pathol 2018;11(6):3141-3146 www.ijcep.com /ISSN:1936-2625/IJCEP0075771 Case Report Metastasis of pancreatic cancer within primary colon cancer by overtaking the stromal microenvironment Takeo Nakaya1, Hisashi Oshiro1, Takumi Saito2, Yasunaru Sakuma2, Hisanaga Horie2, Naohiro Sata2, Akira Tanaka1 Departments of 1Pathology, 2Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan Received March 10, 2018; Accepted April 15, 2018; Epub June 1, 2018; Published June 15, 2018 Abstract: We report a unique case of a 74-old man, who presented with double cancers, showing metastasis of pancreatic cancer to colon cancer. Histopathological examination after surgery revealed that the patient had as- cending colon cancer, which metastasized to the liver (pT4N0M1), as well as pancreatic cancer (pT2N1M1) that metastasized to the most invasive portion of the colon cancer, namely the serosal to subserosal layers. Although the mechanisms for this scenario have yet to be elucidated, we speculate that the metastatic pancreatic carcinoma overtook the stromal microenvironment of the colon cancer. Namely, the cancer microenvironment enriched by can- cer-associated fibroblasts, which supported the colon cancer, might be suitable for the invasion and engraftment by pancreatic carcinoma. The similarity of histological appearance might make it difficult to distinguish metastatic pancreatic carcinoma within colon cancer. Furthermore, the metastasis of pancreatic carcinoma in colon carcinoma might be more common, despite it not having been previously reported. Keywords: Cancer metastasis, metastatic pancreatic cancer, colon cancer, double cancer, tumor microenviron- ment Introduction Case report Prevention and control of cancer metastasis is Clinical history one of the most important problems in cancer care [1-4].
    [Show full text]
  • Pecoma—A Rare Liver Tumor
    Journal of Clinical Medicine Article PEComa—A Rare Liver Tumor Marek Krawczyk 1, Bogna Ziarkiewicz-Wróblewska 2, Tadeusz Wróblewski 1, Joanna Podgórska 3, Jakub Grzybowski 2, Beata Gierej 2, Piotr Krawczyk 1, Paweł Nyckowski 4, Oskar Kornasiewicz 1, Waldemar Patkowski 1, Piotr Remiszewski 1, Krzysztof Zaj ˛ac 1 and Michał Gr ˛at 1,* 1 Department of General, Transplant and Liver Surgery, Medical University Warsaw, 02-097 Warsaw, Poland; [email protected] (M.K.); [email protected] (T.W.); [email protected] (P.K.); [email protected] (O.K.); [email protected] (W.P.); [email protected] (P.R.); [email protected] (K.Z.) 2 Department of Pathology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] (B.Z.-W.); [email protected] (J.G.); [email protected] (B.G.) 3 2nd Department of Clinical Radiology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of General, Gastroenterological and Oncological Surgery, Medical University Warsaw, 02-097 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-22-599-2545 Abstract: PEComa (perivascular epithelioid cell tumor) is a rare liver tumor. Decisions regarding patient management are currently based on a few small case series. The aim of this study was to report the clinicopathological features of PEComa in order to provide guidance for management, complemented by our own experience. This retrospective observational study included all patients with PEComa who underwent surgical treatment in two departments between 2002 and 2020.
    [Show full text]
  • Primary Hepatic Neuroendocrine Carcinoma: Report of Two Cases and Literature Review
    The Jackson Laboratory The Mouseion at the JAXlibrary Faculty Research 2018 Faculty Research 3-1-2018 Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. Zi-Ming Zhao The Jackson Laboratory, [email protected] Jin Wang Ugochukwu C Ugwuowo Liming Wang Jeffrey P Townsend Follow this and additional works at: https://mouseion.jax.org/stfb2018 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons Recommended Citation Zhao, Zi-Ming; Wang, Jin; Ugwuowo, Ugochukwu C; Wang, Liming; and Townsend, Jeffrey P, "Primary hepatic neuroendocrine carcinoma: report of two cases and literature review." (2018). Faculty Research 2018. 71. https://mouseion.jax.org/stfb2018/71 This Article is brought to you for free and open access by the Faculty Research at The ousM eion at the JAXlibrary. It has been accepted for inclusion in Faculty Research 2018 by an authorized administrator of The ousM eion at the JAXlibrary. For more information, please contact [email protected]. Zhao et al. BMC Clinical Pathology (2018) 18:3 https://doi.org/10.1186/s12907-018-0070-7 CASE REPORT Open Access Primary hepatic neuroendocrine carcinoma: report of two cases and literature review Zi-Ming Zhao1,2*† , Jin Wang3,4,5†, Ugochukwu C. Ugwuowo6, Liming Wang4,8* and Jeffrey P. Townsend2,7* Abstract Background: Primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare. The diagnosis of PHNEC remains challenging—partly due to its rarity, and partly due to its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.
    [Show full text]
  • Carcinoid Case Presentation and Discussion: the American Perspective
    Endocrine-Related Cancer (2003) 10 489–496 NEUROENDOCRINE TUMOURS Carcinoid case presentation and discussion: the American perspective R R P Warner Department of Medicine, Gastrointestinal Division, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, New York 10029, USA (Requests for offprints should be addressed toRRPWarner; Email: rwarner—[email protected]) Abstract The rationale underlying an aggressive approach in the management of some carcinoid patients is explained and illustrated by the presented case of a middle-aged man with advanced classic typical midgut carcinoid. The patient exhibited somatostatin receptor scintigraphy-positive massive liver metastases, carcinoid syndrome, severe tricuspid and pulmonic cardiac valve disease with congestive heart failure, ascites and malnutrition. He had been treated for several years with supportive medications and biotherapy including octreotide and alpha interferon but his tumor eventually progressed and his overall condition was markedly deteriorated when he first sought more aggressive treatment. This consisted of prompt replacement of both tricuspid and pulmonic valves, followed by hepatic artery chemoembolus (HACE) injection and then surgical tumor debulking including excision of the primary tumor in the small intestine. In addition, radiofrequency ablation was utilized to reduce the volume of metastases in the liver. Prophylactic cholecystectomy was also performed and a biopsy of tumor was submitted for cell culture drug resistance testing. This was followed by systemic chemotherapy utilizing the drug (docetaxel) which the in vitro studies suggested as most likely to be effective. His excellent response to this succession of treatments exemplifies the successful application of aggressive sequential multi-modality therapy. Endocrine-Related Cancer (2003) 10 489–496 Introduction and sometimes aggressive treatment (O¨ berg 1998).
    [Show full text]
  • Familial Adenomatous Polyposis FAP Booklet 10/18/2001 2:35 PM Page Iv
    FAP Booklet 10/18/2001 2:35 PM Page ii The Johns Hopkins Guide for Patients and Families: Familial Adenomatous Polyposis FAP Booklet 10/18/2001 2:35 PM Page iv The Johns Hopkins Guide for Patients and Families: Familial Adenomatous Polyposis © 2000 The Johns Hopkins University FAP Booklet 10/18/2001 2:35 PM Page vi THE JOHNS HOPKINS GUIDE FOR PATIENTS AND FAMILIES: FAMILIAL ADENOMATOUS POLYPOSIS TABLE OF CONTENTS Introduction ……………………………………………………………………………1 What are Polyps ………………………………………………………………………2 What is Familial Adenomatous Polyposis (FAP)? …………………………………2 What is Attenuated FAP (AFAP)?……………………………………………………2 What is the Gastrointestinal Tract? …………………………………………………3 How is FAP Inherited? ………………………………………………………………4 DNA Test for FAP ……………………………………………………………………4 Why is Early Diagnosis Important? …………………………………………………6 Exam Guidelines for People At Risk ………………………………………………6 What are the Symptoms of FAP?.……………………………………………………7 Other Tumors Associated with FAP…………………………………………………7 How is FAP Diagnosed?………………………………………………………………8 What is the Treatment? ………………………………………………………………9 Sexual Function and Childbirth After Surgery ……………………………………9 Guidelines for Follow Up Care for People with FAP ……………………………0 Support Groups for Individuals and Families ……………………………………11 Resources ……………………………………………………………………………12 Publications …………………………………………………………………………14 Glossary ………………………………………………………………………………15 Appendix ……………………………………………………………………………18 FAP Booklet 10/18/2001 2:35 PM Page vii FAP Booklet 10/18/2001 2:35 PM Page 1 INTRODUCTION This booklet is written for individuals with familial adenomatous polyposis (FAP) and their families. The information provided is intended to add to, and is not a substi- tute for, discussions with doctors, genetic counselors, nurses, and other members of the health care team. We encourage you to read the entire booklet in the order in which it is written since each section is built on information in preceding sections.
    [Show full text]
  • What Is a Gastrointestinal Carcinoid Tumor?
    cancer.org | 1.800.227.2345 About Gastrointestinal Carcinoid Tumors Overview and Types If you have been diagnosed with a gastrointestinal carcinoid tumor or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is a Gastrointestinal Carcinoid Tumor? Research and Statistics See the latest estimates for new cases of gastrointestinal carcinoid tumor in the US and what research is currently being done. ● Key Statistics About Gastrointestinal Carcinoid Tumors ● What’s New in Gastrointestinal Carcinoid Tumor Research? What Is a Gastrointestinal Carcinoid Tumor? Gastrointestinal carcinoid tumors are a type of cancer that forms in the lining of the gastrointestinal (GI) tract. Cancer starts when cells begin to grow out of control. To learn more about what cancer is and how it can grow and spread, see What Is Cancer?1 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 To understand gastrointestinal carcinoid tumors, it helps to know about the gastrointestinal system, as well as the neuroendocrine system. The gastrointestinal system The gastrointestinal (GI) system, also known as the digestive system, processes food for energy and rids the body of solid waste. After food is chewed and swallowed, it enters the esophagus. This tube carries food through the neck and chest to the stomach. The esophagus joins the stomachjust beneath the diaphragm (the breathing muscle under the lungs). The stomach is a sac that holds food and begins the digestive process by secreting gastric juice. The food and gastric juices are mixed into a thick fluid, which then empties into the small intestine.
    [Show full text]
  • Familial Occurrence of Carcinoid Tumors and Association with Other Malignant Neoplasms1
    Vol. 8, 715–719, August 1999 Cancer Epidemiology, Biomarkers & Prevention 715 Familial Occurrence of Carcinoid Tumors and Association with Other Malignant Neoplasms1 Dusica Babovic-Vuksanovic, Costas L. Constantinou, tomies (3). The most frequent sites for carcinoid tumors are the Joseph Rubin, Charles M. Rowland, Daniel J. Schaid, gastrointestinal tract (73–85%) and the bronchopulmonary sys- and Pamela S. Karnes2 tem (10–28.7%). Carcinoids are occasionally found in the Departments of Medical Genetics [D. B-V., P. S. K.] and Medical Oncology larynx, thymus, kidney, ovary, prostate, and skin (4, 5). Ade- [C. L. C., J. R.] and Section of Biostatistics [C. M. R., D. J. S.], Mayo Clinic nocarcinomas and carcinoids are the most common malignan- and Mayo Foundation, Rochester, Minnesota 55905 cies in the small intestine in adults (6, 7). In children, they rank second behind lymphoma among alimentary tract malignancies (8). Carcinoids appear to have increased in incidence during the Abstract past 20 years (5). Carcinoid tumors are generally thought to be sporadic, Carcinoid tumors were originally thought to possess a very except for a small proportion that occur as a part of low metastatic potential. In recent years, their natural history multiple endocrine neoplasia syndromes. Data regarding and malignant potential have become better understood (9). In the familial occurrence of carcinoid as well as its ;40% of patients, metastases are already evident at the time of potential association with other neoplasms are limited. A diagnosis. The overall 5-year survival rate of all carcinoid chart review was conducted on patients indexed for tumors, regardless of site, is ;50% (5).
    [Show full text]
  • Carcinoid Syndrome Caused by a Serotonin-Secreting Pituitary Tumour
    L A Lyngga˚ rd and others Carcinoid syndrome from 170:2 K5–K9 Case Report pituitary tumour Carcinoid syndrome caused by a serotonin-secreting pituitary tumour Correspondence ˚ Louise A Lynggard, Eigil Husted Nielsen and Peter Laurberg should be addressed Department of Endocrinology, Aalborg University Hospital, Hobrovej 18-22, DK-9000 Aalborg, Denmark to P Laurberg Email [email protected] Abstract Background: Neuroendocrine tumours are most frequently located in the gastrointestinal organ system or in the lungs, but they may occasionally be found in other organs. Case: We describe a 56-year-old woman suffering from a carcinoid syndrome caused by a large serotonin-secreting pituitary tumour. She had suffered for years from episodes of palpitations, dyspnoea and flushing. Cardiac disease had been suspected, which delayed the diagnosis, until blood tests revealed elevated serotonin and chromogranin A in plasma. The somatostatin receptor (SSR) scintigraphy showed a single-positive focus in the region of the pituitary gland and MRI showed a corresponding intra- and suprasellar heterogeneous mass. After pre-treatment with octreotide leading to symptomatic improvement, the patient underwent trans-cranial surgery with removal of the tumour. This led to a clinical improvement and to a normalisation of SSR scintigraphy, as well as serotonin and chromogranin A levels. Conclusion: To our knowledge, this is the first reported case of a serotonin-secreting tumour with a primary location in the pituitary. European Journal of Endocrinology (2014) 170, K5–K9 European Journal of Endocrinology Introduction The carcinoid syndrome consists of a variety of symptoms neuroendocrine tumour (NET), most often located in the which typically include episodes of dry flushing with or gut or in the lungs.
    [Show full text]